Heatwurx (PCSA) Competitors $0.41 +0.01 (+3.46%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$0.39 -0.02 (-4.10%) As of 08:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PCSA vs. COEP, CRVO, HOWL, OKYO, JATT, ABVC, PMVP, PRLD, GANX, and BYSIShould you be buying Heatwurx stock or one of its competitors? The main competitors of Heatwurx include Coeptis Therapeutics (COEP), CervoMed (CRVO), Werewolf Therapeutics (HOWL), OKYO Pharma (OKYO), JATT Acquisition (JATT), ABVC BioPharma (ABVC), PMV Pharmaceuticals (PMVP), Prelude Therapeutics (PRLD), Gain Therapeutics (GANX), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry. Heatwurx vs. Its Competitors Coeptis Therapeutics CervoMed Werewolf Therapeutics OKYO Pharma JATT Acquisition ABVC BioPharma PMV Pharmaceuticals Prelude Therapeutics Gain Therapeutics BeyondSpring Heatwurx (NASDAQ:PCSA) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings. Do insiders and institutionals have more ownership in PCSA or COEP? 91.9% of Heatwurx shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 2.4% of Heatwurx shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, PCSA or COEP? Heatwurx has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.49, indicating that its stock price is 149% less volatile than the S&P 500. Do analysts rate PCSA or COEP? Heatwurx presently has a consensus target price of $1.00, indicating a potential upside of 144.02%. Given Heatwurx's stronger consensus rating and higher possible upside, research analysts clearly believe Heatwurx is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is PCSA or COEP more profitable? Coeptis Therapeutics' return on equity of -201.73% beat Heatwurx's return on equity.Company Net Margins Return on Equity Return on Assets HeatwurxN/A -342.36% -243.48% Coeptis Therapeutics N/A -201.73%-108.46% Which has stronger valuation & earnings, PCSA or COEP? Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHeatwurxN/AN/A-$11.85M-$2.32-0.18Coeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.64 Does the media refer more to PCSA or COEP? In the previous week, Coeptis Therapeutics had 2 more articles in the media than Heatwurx. MarketBeat recorded 3 mentions for Coeptis Therapeutics and 1 mentions for Heatwurx. Heatwurx's average media sentiment score of 0.95 beat Coeptis Therapeutics' score of 0.90 indicating that Heatwurx is being referred to more favorably in the media. Company Overall Sentiment Heatwurx Positive Coeptis Therapeutics Positive SummaryHeatwurx beats Coeptis Therapeutics on 8 of the 13 factors compared between the two stocks. Get Heatwurx News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCSA vs. The Competition Export to ExcelMetricHeatwurxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.94M$2.96B$6.12B$10.45BDividend YieldN/A57.77%5.73%4.78%P/E Ratio-0.1822.7985.3827.36Price / SalesN/A778.16602.69196.46Price / CashN/A172.6337.4661.86Price / Book0.895.5112.516.81Net Income-$11.85M$33.06M$3.32B$276.80M7 Day Performance4.35%0.23%0.60%0.42%1 Month Performance104.39%14.73%10.53%7.86%1 Year Performance-68.95%-1.42%74.30%41.24% Heatwurx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCSAHeatwurx3.27 of 5 stars$0.41+3.5%$1.00+144.0%-67.0%$19.94MN/A-0.1820Gap UpCOEPCoeptis Therapeutics1.3035 of 5 stars$15.55-1.0%N/A+280.3%$75.68MN/A-2.682CRVOCervoMed3.5545 of 5 stars$8.01-1.7%$19.29+140.8%-42.2%$75.41M$9.74M-3.074Analyst DowngradeHOWLWerewolf Therapeutics3.4945 of 5 stars$1.63flat$8.00+390.8%-12.4%$74.54M$1.88M-0.9940News CoverageOKYOOKYO Pharma2.8554 of 5 stars$2.00+2.4%$7.00+250.0%+102.9%$73.49MN/A0.007Gap UpJATTJATT AcquisitionN/A$4.15-8.0%N/A-13.9%$71.59MN/A0.003Gap DownHigh Trading VolumeABVCABVC BioPharma0.8802 of 5 stars$2.96-2.6%N/A+394.0%$71.57M$510K-17.4130PMVPPMV Pharmaceuticals3.0336 of 5 stars$1.32-2.2%$5.50+316.7%-3.4%$71.54MN/A-0.8450Analyst ForecastPRLDPrelude Therapeutics3.4539 of 5 stars$1.25-0.8%$4.00+220.0%-28.8%$71.32M$7M-0.76120GANXGain Therapeutics3.1249 of 5 stars$1.90-3.6%$7.86+313.5%-22.1%$70.82M$50K-3.0220Analyst ForecastGap UpBYSIBeyondSpringN/A$1.71-1.7%N/A-33.7%$70.18M$1.75M0.0080News CoverageHigh Trading Volume Related Companies and Tools Related Companies Coeptis Therapeutics Alternatives CervoMed Alternatives Werewolf Therapeutics Alternatives OKYO Pharma Alternatives JATT Acquisition Alternatives ABVC BioPharma Alternatives PMV Pharmaceuticals Alternatives Prelude Therapeutics Alternatives Gain Therapeutics Alternatives BeyondSpring Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCSA) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and ea...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heatwurx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heatwurx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
